Investor Relations (IR) Questions: MEI Pharma MEIP
Click here to return to the biotech IRQ Index
Answers received: February 2013
1) When is the last time MEIP raised cash through an offering (diluted)?
We completed a $27.5 million private placement in December 2012.
2) How much cash (not cash equivalents) does MEIP have?
As of December 31, 2012, we had cash and cash equivalents of $26.9 million. Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased. We have not broken out cash separately in our reporting.
3) What and approximately when is the next known catalyst?
We plan to initiate a randomized, placebo-controlled Phase II trial of Pracinostat in combination with azacitidine in patients with myelodysplastic syndrome by June. We also expect to report results from our Phase I trial of intravenous ME-344 in patients with solid refractory tumors in June.
4) What is MEIP's quarterly cash burn?
Net cash used in operations for the six months ended December 30, 2012 was $4.6 million. We have not provided guidance on quarterly cash burn.
5) Does MEIP have an existing line of credit and if so how much can they draw against it?
We do not have an existing line of credit.
1) When is the last time MEIP raised cash through an offering (diluted)?
We completed a $27.5 million private placement in December 2012.
2) How much cash (not cash equivalents) does MEIP have?
As of December 31, 2012, we had cash and cash equivalents of $26.9 million. Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased. We have not broken out cash separately in our reporting.
3) What and approximately when is the next known catalyst?
We plan to initiate a randomized, placebo-controlled Phase II trial of Pracinostat in combination with azacitidine in patients with myelodysplastic syndrome by June. We also expect to report results from our Phase I trial of intravenous ME-344 in patients with solid refractory tumors in June.
4) What is MEIP's quarterly cash burn?
Net cash used in operations for the six months ended December 30, 2012 was $4.6 million. We have not provided guidance on quarterly cash burn.
5) Does MEIP have an existing line of credit and if so how much can they draw against it?
We do not have an existing line of credit.
